[ALIM] Alimera Sciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.12 Change: 0.05 (4.67%)
Ext. hours: Change: 0 (0%)

chart ALIM

Refresh chart

Strongest Trends Summary For ALIM

ALIM is in the long-term down -46% below S&P in 2 years and down -90% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Alimera Sciences, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company?s principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient?s eye to a placement site that uses the eye?s natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME; and Dain

Fundamental Ratios
Shares Outstanding EPS-0.5 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 79.82% Sales Growth - Q/Q126.19% P/E-2.68
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-25.76% ROE-61.48% ROI-29.4%
Current Ratio5.86 Quick Ratio5.69 Long Term Debt/Equity0.74 Debt Ratio0.3
Gross Margin88.7% Operating Margin-355.13% Net Profit Margin-242.72% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-200 K Cash From Investing Activities-160 K Cash From Operating Activities-14.7 M Gross Profit3.65 M
Net Profit-9.79 M Operating Profit-10.99 M Total Assets96.83 M Total Current Assets70.31 M
Total Current Liabilities11.99 M Total Debt34.53 M Total Liabilities56.26 M Total Revenue3.94 M
Technical Data
High 52 week1.38 Low 52 week0.75 Last close0.92 Last change-6.11%
RSI46.02 Average true range0.05 Beta0.87 Volume265.7 K
Simple moving average 20 days-4.46% Simple moving average 50 days-8.6% Simple moving average 200 days-10%
Performance Data
Performance Week-4.15% Performance Month-6.1% Performance Quart-13.19% Performance Half-17.84%
Performance Year-26.38% Performance Year-to-date-30.81% Volatility daily2.75% Volatility weekly6.16%
Volatility monthly12.62% Volatility yearly43.72% Relative Volume294.18% Average Volume125.6 K
New High New Low

News

2019-03-06 08:00:00 | Alimera Sciences Announces the Reimbursement of ILUVIENR in France

2019-02-20 10:31:03 | Will Alimera Sciences ALIM Report Negative Q4 Earnings? What You Should Know

2019-02-19 15:26:22 | Edited Transcript of ALIM earnings conference call or presentation 19-Feb-19 2:00pm GMT

2019-02-19 07:00:00 | Alimera Sciences, Inc. to Host Earnings Call

2019-02-18 16:15:00 | Alimera Sciences Reports Record Fourth Quarter and 2018 Results

2019-02-05 07:30:00 | Alimera Sciences Announces Approval for ILUVIENR in Lebanon

2019-02-04 07:30:00 | Alimera Sciences to Report Fourth Quarter and Full Year 2018 Results on February 18, 2019

2019-01-30 11:07:20 | Eye implant is helping treat vision loss in diabetics

2019-01-07 06:30:00 | Alimera Sciences Affirms Record 2018 Revenues

2018-12-21 11:36:47 | What Type Of Shareholder Owns Alimera Sciences, Inc.’s NASDAQ:ALIM?

2018-12-17 07:00:00 | Alimera Sciences Announces Pricing Approval For ILUVIENR in the U.A.E.

2018-11-29 07:15:00 | Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer

2018-11-26 15:30:00 | Alimera Sciences Announces Canadian Regulatory Approval for ILUVIENR

2018-11-21 08:25:00 | Consolidated Research: 2018 Summary Expectations for Texas Instruments, Sino-Global Shipping America, Alimera Sciences, Sypris Solutions, JetPay, and Performant Financial — Fundamental Analysis, Key Performance Indications

2018-11-09 06:30:00 | Alimera Sciences to Present at Upcoming Investor Conferences

2018-11-06 13:10:13 | Edited Transcript of ALIM earnings conference call or presentation 6-Nov-18 2:00pm GMT

2018-11-06 07:30:12 | Alimera Sciences ALIM Reports Q3 Loss, Tops Revenue Estimates

2018-11-06 05:03:10 | Alimera Sciences: 3Q Earnings Snapshot

2018-11-05 18:45:00 | Alimera Sciences Reports Third Quarter 2018 Results

2018-10-23 16:45:00 | Alimera Sciences to Report Third Quarter 2018 Results November 5, 2018

2018-10-22 16:30:00 | Alimera Sciences Announces Six ILUVIENR Posters to be Presented at 2018 American Academy of Ophthalmology

2018-10-15 15:57:44 | How Alimera Sciences Inc NASDAQ:ALIM Can Impact Your Portfolio Volatility

2018-09-17 17:32:00 | Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress

2018-09-13 16:30:00 | Alimera Sciences Announces Three Podium Presentations for ILUVIEN® to be Presented at 2018 Retina Society's Annual Meeting

2018-09-04 17:43:00 | Alimera Sciences Announces Exchange of Series B Preferred Stock for Newly Issued Series C Preferred Stock

2018-08-29 07:30:00 | Alimera Sciences to Present at the 20th Annual HC Wainwright Global Investment Conference

2018-08-28 07:30:00 | Alimera Sciences to Present at the Annual B. Riley Healthcare Conference

2018-08-23 06:42:10 | Alimera Sciences Sees Hammer Chart Pattern: Time to Buy?

2018-07-31 15:08:26 | Edited Transcript of ALIM earnings conference call or presentation 31-Jul-18 1:00pm GMT

2018-07-31 07:00:00 | Alimera Sciences, Inc. to Host Earnings Call

2018-07-30 17:41:35 | Alimera Sciences: 2Q Earnings Snapshot

2018-07-30 16:30:00 | Alimera Sciences Reports Second Quarter 2018 Results

2018-07-18 07:30:00 | Alimera Sciences to Report Second Quarter 2018 Results July 30, 2018

2018-07-11 07:30:00 | Alimera Sciences Announces 8 ILUVIEN® Presentations At The 2018 American Society Of Retina Specialists Annual Meeting

2018-07-05 09:10:42 | Alimera Stock Grew 25 Percent and It Is Just Getting Warmed Up

2018-06-29 14:50:28 | B. Riley FBR: 3 Reasons To Buy Alimera Sciences

2018-06-27 11:24:23 | When Will Alimera Sciences Inc NASDAQ:ALIM Turn A Profit?

2018-06-21 07:30:00 | Alimera Sciences Appoints Mary T. Szela to its Board of Directors

2018-06-11 07:30:00 | The UK National Institute For Health And Care Excellence To Undertake A Partial Review Of The ILUVIEN Reimbursement Guidance Allowing Broader Availability

2018-06-04 07:30:00 | Alimera Sciences Terminates At-the-Market Offering Agreement

2018-05-31 07:30:00 | Alimera Sciences Announces the Reimbursement of ILUVIEN® in Spain

2018-05-22 07:30:00 | Alimera Sciences to Present at the 8th Annual LD Micro Invitational Conference

2018-05-05 07:25:38 | Edited Transcript of ALIM earnings conference call or presentation 3-May-18 1:00pm GMT

2018-05-02 16:15:00 | Alimera Sciences Reports First Quarter 2018 Results

2018-04-24 16:30:00 | Alimera Sciences to Report First Quarter 2018 Results May 2, 2018

2018-04-24 07:30:00 | Alimera Sciences Announces Data from 19 IluvienR Studies to be Presented at 2018 ARVO

2018-03-02 06:05:57 | Edited Transcript of ALIM earnings conference call or presentation 1-Mar-18 2:00pm GMT

2018-03-01 07:40:00 | Alimera Sciences, Inc. to Host Earnings Call

2018-02-28 19:19:39 | Alimera Sciences reports 4Q loss

2018-02-28 16:30:00 | Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results